en · de · es · pt
methods-notes.peptides6908.com › Faq › Chemistry And Receptor Pharmacology — Deep Dive

Chemistry And Receptor Pharmacology — Deep Dive

By Editorial Desk · published 2026-02-18 · last reviewed 2026-03-12 · Faq

Everything below concerns MC1R. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-03-12. Where a claim depends on a specific study, the study is described rather than over-claimed.

Chemistry and Receptor Pharmacology

Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.

Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.

Melanotan-2 Identity And Regulatory Status

Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.

Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.

Melanotan-2 at a glance

PropertyValueNotes
Molecular formulaC50H69N15O9Cyclic heptapeptide, C-terminally amidated
Approximate molecular mass1024 DaMonoisotopic mass of the free peptide
AppearanceWhite to off-white powderTypically supplied as a lyophilised solid
Solubility classSoluble in water and polar solventsAlso dissolves in neutral aqueous buffer
Common synonymsMelanotan II, MT-II, MT-2Described as a melanocortin agonist in early literature

Identity and Chemical Background

The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.

Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.

Related pages on this site

Peptide Identity and Structural Background

Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.

Origins and Research Status

Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.

Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.

Notes from published material

=== Financing === In May 2016, Cerebras raised $27 million in a series A round led by Benchmark, Foundation Capital and Eclipse Ventures. In December 2016, the company raised a series B round led by Coatue Management. In January 2017, it raised a series C round led by VY Capital. In November 2018, Cerebras raised $88 million in a series D round, making the company a unicorn. Investors in this round included Altimeter, VY Capital, Coatue, Foundation Capital, Benchmark, and Eclipse. In November 2019, Cerebras raised $270 million in a series E round at a valuation of $2.4 billion. In November 2021, Cerebras raised $250 million in a Series F round, valuing the company at over $4 billion and bringing its total financing to $720 million. The Series F financing round was led by Alpha Wave Ventures and Abu Dhabi Growth Fund (ADG). In July, August, and September 2024, the company raised $85 million in a series F-1 round, selling shares for $14.66 each. In September 2025, the company raised $1.1 billion in a Series G round, selling shares for $36.23 each, or a valuation of $8.1 billion. In January 2026, the company raised $1.0 billion in a Series H round, selling shares for $89.01 each. In this round, Benchmark invested $225 million, while Alpha Wave and funds managed by Fidelity Investments each invested $100 million. On May 14, 2026, the company became a public company via the largest U.S. technology initial public offering since 2019, raising $5.55 billion by selling 30 million shares at $185 each and opening on Nasdaq at $350, valuing the company at $95 billion.

From 1933 onwards, poet Victor Neuburg edited a section called "The Poet's Corner" in a British newspaper, the Sunday Referee. Here he encouraged new talent by awarding weekly prizes. One prize went to the then-unknown Thomas, and the publisher of the Sunday Referee sponsored and Neuburg arranged for the publication of Thomas's first book, 18 Poems, in December 1934. The anthology was published by Fortune Press, in part a vanity publisher that did not pay its writers and expected them to buy a certain number of copies themselves. 18 Poems was noted for its visionary qualities which led to critic Desmond Hawkins writing that the work was "the sort of bomb that bursts no more than once in three years". The volume was critically acclaimed, netting him new admirers from the London poetry world, including Edith Sitwell and Edwin Muir. When "Light breaks where no sun shines" appeared in The Listener in 1934, it caught the attention of three senior figures in literary London, T. S. Eliot, Geoffrey Grigson and Stephen Spender. In December 1935, Thomas contributed the poem "The Hand That Signed the Paper" to Issue 18 of the bi-monthly New Verse. In 1936, his next collection Twenty-five Poems, published by J. M. Dent, also received much critical praise. Two years later, in 1938, Thomas won the Oscar Blumenthal Prize for Poetry; it was also the year in which New Directions offered to be his publisher in the United States. In all, he wrote half his poems while living at Cwmdonkin Drive before moving to London. During this time Thomas's reputation for heavy drinking developed.

A 2017 systematic review and meta-analysis of suvorexant for the treatment of insomnia found that the medication significantly increased the rate of somnolence by 3.5-fold, daytime sleepiness/sedation by 3.1-fold, fatigue by 2.1-fold, abnormal dreams by 2.1-fold, and dry mouth by 2.0-fold. Conversely, suvorexant did not significantly differ from placebo in the rates of any other assessed adverse effects. This included back pain, diarrhea, dizziness, falls, headache, car accidents/traffic violations, nasopharyngitis, nausea, potential drug misuse, suicidal ideation, complex sleep behaviors, hypnagogic or hypnopompic hallucinations, and sleep paralysis. The overall risk of any adverse event was increased 1.07-fold while discontinuation due to adverse events was unchanged (RRTooltip relative risk=0.93, 95% CITooltip confidence interval 0.60 to 1.44). Tolerance, dependence, withdrawal, and rebound effects do not appear to occur with suvorexant in the treatment of insomnia at studied doses. In three-month clinical studies, no rebound insomnia as assessed by measures of sleep onset or maintenance was observed with discontinuation of suvorexant at doses of 15 to 40 mg. Similarly, no withdrawal effects were observed with discontinuation of suvorexant at these doses. However, in other reports, some tolerance as assessed by diminishing somnolence and rebound insomnia upon discontinuation has been noted. The orexin neuropeptides augment the signaling of the mesolimbic dopamine reward pathway and are thought to potentiate hedonic tone.

High-intensity pulsed electric fields are being used as an alternative to heat pasteurization in fruit juices. Heat treatments sometimes fail to make a quality, microbiologically stable product. However, it was found that processing with high-intensity pulsed electric fields (PEF) can be applied to fruit juices to provide a shelf-stable and safe product. In addition, it was found that pulsed electric fields provide a fresh-like product with high nutritional value. Pulsed electric field processing is a type of nonthermal method for food preservation. Pulsed electric fields use short pulses of electricity to inactivate microbes. In addition, the use of PEF results in minimal detrimental effects on the quality of the food. PEFs kill microorganisms and provide better maintenance of the original colour, flavour, and nutritional value of the food as compared to heat treatments. This method of preservation works by placing two electrodes between liquid juices, then applying high-voltage pulses for microseconds to milliseconds. The high-voltage pulses have an intensity in the range of 10 to 80 kV/cm. The processing time of the juice is calculated by multiplying the number of pulses by the effective pulse duration. The high voltage of the pulses produces an electric field that results in the inactivation of microbes that may be present in the juice. The PEF temperatures are below the temperatures used in thermal processing. After the high-voltage treatment, the juice is aseptically packaged and refrigerated.

== See also == Biological half-life, the time it takes for a substance to lose half of its pharmacologic, physiologic, or radiologic activity Effective half-life, the effective radioactive half-life in organisms after accounting for excretion Half-life of knowledge, the amount of time that has to elapse before half of the knowledge or facts in a particular area is superseded or shown to be untrue Half a Life (disambiguation)

Sources: en.wikipedia.org

Further detail

==== Phytoplankton and bacteria ==== The δD of lipids from phytoplankton is largely affected by δD of water, and there seems to be a linear correlation between those two values. The δD of most other biosynthetic products in phytoplankton or cyanobacteria are more negative than that of the surrounding water. The δD values of fatty acids in methanotrophs living in seawater lie between −50 and −170‰, and that of sterols and hopanols range between −150 and −270‰. The HIC of photoautotrophs can be estimated using the equation,

Once approved, the political reform referendum was convened for December 15. The government did not give any opportunity to the opposition to present its position ─ abstention ─ in the media it controlled, especially in the most influential one, the television ─ nor even in the radio ─ and deployed a formidable campaign in favor of the YES, so the result of the referendum did not bring any surprise: there was a high turnout, except in the Basque Country, and the YES won with 94.2% of the votes, while the NO, defended by the búnker, only got 2.6%. The "political reform", and implicitly the monarchy and its government, were thus legitimized by the popular vote. From that moment on, the opposition's demand for the formation of a government of "broad democratic consensus" no longer made sense. It would be the Suárez government that would assume the task that the opposition had assigned to that government: to call general elections. During the last week of January 1977 the most delicate moment of the transition before the elections took place, as the Francoists in the búnker set out to stop the process of change by creating a climate of panic that would justify the intervention of the Army. The first provocation came in Madrid's Gran Vía, when a student, Arturo Ruiz, who was taking part in a pro-amnesty demonstration was killed by thugs of the extreme right-wing group Fuerza Nueva ─ in the demonstration protesting the crime a demonstrator, María Luz Nájera, was killed by a police smoke canister.

Non-surgical rhinoplasty is a medical procedure in which injectable fillers, such as collagen or hyaluronic acid, are used to alter and shape a person's nose without invasive surgery. The procedure fills in depressed areas on the nose, lifting the angle of the tip or smoothing the appearance of bumps on the bridge. The procedure does not alter nose size, though it can be used to correct some functional birth defects. Originally developed at the turn of the twenty-first century, early attempts used biologically harmful soft-tissue fillers such as paraffin wax and silicone. After 2000, physicians use minimally invasive techniques using modern fillers.

He framed Latino immigrants, particularly those from Mexico, as threats to the nation's social and genetic "fitness." He promoted sterilization as a means of racial and social improvement. Some of the factors that may catapulted the movement behind the sterilization abuse in Latina women in the state of California, began with one of the earliest organizations in eugenic sterilizations in the U.S., the Human Betterment Foundation (HBF), the Sterilization Act of 1909, and the Immigration Act of 1924. The California Act of 1909 was one of the major legal and political influences that established authority for doctors and psychiatrists of state hospitals and mental institutions to perform sterilizations on the people unfit to function in society because of their intelligence levels, presumed future deviant behavior and sexual activity. With that established, organizations such as the Human Betterment Foundation came to be the organization that held these ideologies and promote eugenic sterilizations and the Immigration Act of 1924 further developed the idea that labor-migrants were needed, but women and children were not as there was a fear of Latino and Immigrant invasion.

Sources: en.wikipedia.org

Supporting material

== Society and culture == Depictions of heart attacks in popular media often include collapsing or loss of consciousness which are not common symptoms; these depictions contribute to widespread misunderstanding about the symptoms of myocardial infarctions, which in turn contributes to people not getting care when they should.

Chanterelle is the common name of several species of agaricomycetous fungi in the genera Cantharellus, Craterellus, Gomphus and Polyozellus. These fungi are orange, yellow or white, meaty and funnel-shaped. On the lower surface, most species have rounded, forked folds that run almost all the way down the stipe, which tapers down from the cap. Many species emit a fruity aroma and often have a mildly peppery taste. Chanterelles are found in Eurasia, North America and Africa, typically growing in forested areas. They initially gained popularity as an edible mushroom in the 18th century via their inclusion in French cuisine.

==== Iron import ==== Most cell types take up iron primarily through receptor-mediated endocytosis via transferrin receptor 1 (TFR1), transferrin receptor 2 (TFR2) and GAPDH. TFR1 has a 30-fold higher affinity for transferrin-bound iron than TFR2 and thus is the main player in this process. The higher order multifunctional glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) also acts as a transferrin receptor. Transferrin-bound ferric iron is recognized by these transferrin receptors, triggering a conformational change that causes endocytosis. Iron then enters the cytoplasm from the endosome via importer DMT1 after being reduced to its ferrous state by a STEAP family reductase. Alternatively, iron can enter the cell directly via plasma membrane divalent cation importers such as DMT1 and ZIP14 (Zrt-Irt-like protein 14). Again, iron enters the cytoplasm in the ferrous state after being reduced in the extracellular space by a reductase such as STEAP2, STEAP3 (in red blood cells), Dcytb (in enterocytes) and SDR2.

=== Alzheimer's disease === The ATP-binding cassette protein ABCC1 has received attention in the last decade due to its possible connection with Alzheimer's disease. One of the more prominent signs of Alzheimer's disease is the accumulation of β-amyloid proteins in the brain. As these proteins accumulate, they begin to form plaques that interfere with signaling between cells of the nervous system found within the brain. Due to its presence in the choroid plexus and blood-brain barrier and its ability to transport multiple kinds of molecules out of cells, ABCC1 has been a point of interest in many Alzheimer's disease studies. The transporter protein has been shown to decrease β-amyloid accumulation by nearly 80 percent when activated, leading researchers to further investigation on its use in future treatments of Alzheimer's and other neurological disorders.

== Cut anatomy and structure == The sirloin steak has several muscles that define the texture and flavor of different cuts. The sirloin does not do much work in supporting the cow, and so does not contain much reinforcing connective tissue. This makes the sirloin tender. The top sirloin primarily contains the Gluteus medius, along with the gluteus accessorius, gluteus profundus, and part of the biceps femoris. During butchery, these parts are separated along natural seams. These muscles differ in size and function. The gluteus medius is the largest and most prominent portion of the steak. These muscles contain connective tissue that contributes to differing tenderness between cuts. The gluteus medius cut is consistently tender. Heavily worked muscles, like the biceps femoris, are often firmer and more flavorful. The top sirloin cooks quicker than the bottom sirloin and is good for pan-searing and grilling. The bottom sirloin contains more muscles and is typically roasted or braised.

Sources: en.wikipedia.org

Frequently asked questions

Is melanotan II identical to alpha-melanocyte-stimulating hormone?

No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.

How does melanotan II differ from afamelanotide?

Afamelanotide is the linear analogue [Nle4-D-Phe7]-alpha-MSH, sometimes called melanotan I, while melanotan II is cyclic and carries three further substitutions. The two are distinct molecules and are not interchangeable in analytical testing.

Is the receptor binding profile well established?

Binding to the four melanocortin receptor subtypes is well documented in vitro. The relative contribution of each subtype to whole-body effects in humans is far less certain.

Is melanotan II approved for medical use?

No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.

Network